Enfusion initiated with Neutral on valuation at Piper Sandler

Piper Sandler initiated coverage of Enfusion with a Neutral rating and $11 price target, which equates to 5% upside to the current price. The analyst thinks Enfusion’s cloud-native platform has advantages over legacy point solutions that require challenging integrations. However, the firm believes the shares are fairly valued at current levels.